MAPT and Alzheimer disease: Exploration of agents that inhibit tauopathy progression is important as recent studies implicate pre-fibrillar hyperphosphorylated tau as the toxic species in AD, CTE, and other neurodegenerative diseases, therefore, re-establishing the interest in tau kinase inhibitors development at putative neurotherapies, which could translate into human clinical trials.